Harrow Health

Yahoo Finance • 2 days ago

Harrow Health Q3 2025 Earnings Preview

* Harrow Health (HROW [https://seekingalpha.com/symbol/HROW]) is scheduled to announce Q3 earnings results on Monday, November 10th, after market close. * The consensus EPS Estimate is $0.29 [https://seekingalpha.com/symbol/HROW/earnin... Full story

Yahoo Finance • 14 days ago

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025

NASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the third quarter en... Full story

Yahoo Finance • 27 days ago

13 Top Stocks With Huge Upside Potential To Buy Now

Buying stocks when the market is setting all-time highs can be a bit nerve-wracking. On the one hand, markets often continue to make new highs once they break through to new records. Conversely, nothing goes up in a straight line. After ba... Full story

Yahoo Finance • last month

Harrow, Inc. (HROW): A Bull Case Theory

We came across a bullish thesis on Harrow, Inc. on Make Money, Make Time’s Substack by Oliver | MMMT Wealth. In this article, we will summarize the bulls’ thesis on HROW. Harrow, Inc.'s share was trading at $47.88 as of September 24th. HRO... Full story

Yahoo Finance • last month

Noteworthy Monday Option Activity: SANM, HROW, ASPN

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Sanmina Corp (Symbol: SANM), where a total volume of 3,360 contracts has been traded thus far today, a contract volume wh... Full story

Yahoo Finance • last month

Harrow to buy Melt Pharmaceuticals

Harrow (NASDAQ:HROW [https://seekingalpha.com/symbol/HROW]) to acquire [https://seekingalpha.com/pr/20245629-harrow-to-acquire-melt-pharmaceuticals] Melt Pharmaceuticals, a clinical-stage pharmaceutical company pioneering non-opioid, non-I... Full story

Yahoo Finance • last month

Harrow to Acquire Melt Pharmaceuticals

NASHVILLE, Tenn., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into an agreement to acquire Melt Pharmaceuti... Full story

Yahoo Finance • last month

Harrow Launches Harrow Access for All (HAFA)

HAFA to Expand Harrow’s Innovative Market AccessModel Across Ophthalmic Portfolio Program will be available in late 2025 through the HarrowAccess.com Portal NASHVILLE, Tenn., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a... Full story

Yahoo Finance • 2 months ago

Harrow Announces Agenda and Speakers for Investor & Analyst Day

NASHVILLE, Tenn., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the agenda for its upcoming Investor & Analyst Day on Friday, Sep... Full story

Yahoo Finance • 2 months ago

Implied FYX Analyst Target Price: $122

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 2 months ago

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private offering (the “Offering”) of $250.0 mi... Full story

Yahoo Finance • 2 months ago

Harrow launches $250M debt offering

* Harrow (NASDAQ:HROW [https://seekingalpha.com/symbol/HROW]) has commenced a private offering of $250.0 million aggregate principal amount of senior unsecured notes due 2030. * The company plans to use proceeds from the offering to fu... Full story

Yahoo Finance • 2 months ago

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

Announces Commitment for New $40 Million Revolving Credit Facility Issues Conditional Notice of Redemption of 11.875% Senior Notes due 2027 NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider... Full story

Yahoo Finance • 2 months ago

HARROW INC (NASDAQ:HROW) Presents High Growth Momentum and Technical Breakout Opportunity

Harrow Inc (NASDAQ:HROW [https://www.chartmill.com/stock/quote/HROW]) appears as an interesting candidate for investors using a high growth momentum strategy paired with technical breakout analysis. This method centers on finding companies... Full story

Yahoo Finance • 3 months ago

Form 8K Harrow Health Inc For: 25 August

... Full story

Yahoo Finance • 3 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW).  Such investors are advised to contact Danielle Peyton at newaction@poml... Full story

Yahoo Finance • 3 months ago

Harrow Announces Second-Quarter 2025 Financial Results

Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year periodGAAP net income of $5.0 millionAdjusted EBITDA of $17.0 millionCash and cash equivalen... Full story

Yahoo Finance • 3 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW).  Such investors are advised to contact Danielle Peyton at newaction@poml... Full story

Yahoo Finance • 3 months ago

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

NASHVILLE, Tenn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in H.C. Wainwright’s 5th Annual Ophthalmology Conference... Full story

Yahoo Finance • 4 months ago

H.C. Wainwright reiterates Buy rating on Harrow Health stock at $60 target

Investing.com - H.C. Wainwright has reiterated its Buy rating and $60.00 price target on Harrow Health (NASDAQ:HROW), currently trading at $36.14, following the company’s announcement of a definitive agreement with Samsung (KS:005930) Bioe... Full story